Company intelligence / Profile preview

Synthetica Pioneering

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Synthetica Pioneering has not yet reported clinical results but recently raised Series A funding to advance its genetically engineered oncolytic bacterial therapies for solid tumors into first-in-human clinical trials.

Therapeutic areas: Oncology
Modalities: Bacterial therapySynthetic biology-based therapy
Industry: Biotech

Partnerships

Boehringer Ingelheim Venture Fund (investor and strategic partner)Temasek (investor)Lenovo Capital (investor)Fosun Health Capital (investor)ATLATL Summer Fund (investor)

Beyond the preview

Go deeper on Synthetica Pioneering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthetica Pioneering.

Explore the full profile